All In Biotech

Drug Trial Radar · NCT06857227

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis

A Randomized Controlled Phase l Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of GNC-038 Tetra-specific Antibody Injection in Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Mar 17, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Mar 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • GNC-038Drug

    Administration by intravenous infusion. Once a week (IV, QW), twice in total.

  • PlaceboDrug

    The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to approximately 28 days
  2. Phase Ia: Maximum tolerated dose (MTD) or Maximum administered dose (MAD)Time frame: Up to approximately 28 days
  3. Phase Ia: Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
  4. Phase Ia: CmaxTime frame: Up to approximately 24 months
  5. Phase Ia: TmaxTime frame: Up to approximately 24 months
  6. Phase Ia: T1/2Time frame: Up to approximately 24 months
  7. Phase Ia: AUC0-tTime frame: Up to approximately 24 months
  8. Phase Ia: CL (Clearance)Time frame: Up to approximately 24 months
  9. Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
  10. Phase Ib: Proportion of patients meeting ACR20 remission criteriaTime frame: Up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.